Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems

  • P. Cohen
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 167)


Protein Phosphatase Protein Tyrosine Phosphatase Human Clinical Trial Protein Kinase Inhibitor Specific Protein Kinase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR (1995) PD98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 270:27489–27494PubMedGoogle Scholar
  2. Armstrong CG, Doherty MJ, Cohen PTW (1998) Identification of the separate domains in the hepatic glycogen-targeting subunit of protein phosphatase 1 that interact with phosphorylase a, glycogen and protein phosphatase 1. Biochem J 336:699–704PubMedGoogle Scholar
  3. Bain J, McLauchlan H, Elliott M, Cohen P (2003) The specificities of protein kinase inhibitors: an update. Biochem J 371:199–204CrossRefPubMedGoogle Scholar
  4. Brown EJ, Beal PA, Keith CT, Chen J, Shin TB, Schreiber SL (1995) Control of p70S6 kinase by kinase activity of FRAP in vivo. Nature 377:441–446CrossRefPubMedGoogle Scholar
  5. Cline GW, Johnson K, Regittnig W, Perret P, Tozzo E, Xiao L, Damico C, Schulman GI (2002) Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 51:2903–2910PubMedGoogle Scholar
  6. Cohen P (2002a) The origins of protein phosphorylation. Nat Cell Biol 4:E127–E130CrossRefPubMedGoogle Scholar
  7. Cohen P (2002b) Protein kinases—the major drug targets of the twenty-first century? Nat Rev Drug Discov 1:309–315CrossRefPubMedGoogle Scholar
  8. Cross DA, Culbert AA, Chalmers KA, Facci L, Skaper SD, Reith AD (2001) Selective small molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J Neurochem 77:94–102PubMedCrossRefGoogle Scholar
  9. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stress and interleukin-1. FEBS Lett 364:229–233CrossRefPubMedGoogle Scholar
  10. Davies SP, Reddy H, Caivano M, Cohen P (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351:95–105CrossRefPubMedGoogle Scholar
  11. Elchebly M, Payette P, Michaliszyn E, Cromlish W, Collins S, Loy AL, Normandin D, Cheng A, Himms-Hagen J, Chan CC, Ramachandran C, Gresser MJ, Tremblay ML, Kennedy BP (1999) Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase 1B gene. Science 282:1544–1548Google Scholar
  12. Eyers PA, Craxton M, Morrice N, Cohen P, Goedert M (1998) Conversion of SB-203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino acid substitution. Chem Biol 5:321–328CrossRefPubMedGoogle Scholar
  13. Eyers PA, Van den Ijssel P, Quinlan R, Goedert M, Cohen P (1999) Use of a drug resistant mutant of stress activated protein kinase 2a/p38 to validate the in vivo specificity of SB203580. FEBS Lett 451: 191–196CrossRefPubMedGoogle Scholar
  14. Gorre ME, Mohammed M, Ellwood K, Hsu N, Pacquette R, Rao PN, Sawyers CL (2001) Clinical resistance of STI 571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880CrossRefPubMedGoogle Scholar
  15. Heitman J, Mowa NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905–909PubMedGoogle Scholar
  16. Kellie S (2003) Protein tyrosine phosphatases: potential roles in disease. In: Watling KJ (ed) Celltransmissions. Sigma-Aldrich, St Louis, pp 3–8Google Scholar
  17. Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807–815CrossRefPubMedGoogle Scholar
  18. MacKintosh C, MacKintosh RW (1994) Inhibitors of protein kinases and phosphatases. Trends Biochem Sci 19:444–447CrossRefPubMedGoogle Scholar
  19. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S, Regan J (2002) Inhibition of p38 MAP kinase by utilising a novel allosteric binding site. Nat Struct Biol 9:268–272CrossRefPubMedGoogle Scholar
  20. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Ma ST, Reeder JW, Samuels I, Slabiak T, Wagman AS, Hammond M-EW, Harrison SD (2003) Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilisation in vitro and in vivo. Diabetes 52:588–595PubMedGoogle Scholar
  21. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J (2000) Structural mechanism for STI 571 inhibition of Abelson tyrosine kinase. Science 289:1938–1942CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • P. Cohen
    • 1
  1. 1.Medical Research Council Protein Phosphorylation UnitUniversity of DundeeDundee, ScotlandUK

Personalised recommendations